941 related articles for article (PubMed ID: 22301798)
21. Clinical development of MVA-based therapeutic cancer vaccines.
Acres B; Bonnefoy JY
Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940
[TBL] [Abstract][Full Text] [Related]
22. MAGE-A3: an immunogenic target used in clinical practice.
Esfandiary A; Ghafouri-Fard S
Immunotherapy; 2015; 7(6):683-704. PubMed ID: 26100270
[TBL] [Abstract][Full Text] [Related]
23. Innovative cancer vaccine strategies based on the identification of tumour-associated antigens.
Ying H; Zeng G; Black KL
BioDrugs; 2001; 15(12):819-31. PubMed ID: 11784213
[TBL] [Abstract][Full Text] [Related]
24. [Epitope peptide vaccine with oncoantigen for cancer and its biomarker].
Hazama S; Maeda K; Oka M
Nihon Rinsho; 2012 Dec; 70(12):2189-93. PubMed ID: 23259395
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy II: Antigens, receptors and costimulation.
Searle PF; Young LS
Cancer Metastasis Rev; 1996 Sep; 15(3):329-49. PubMed ID: 9034595
[TBL] [Abstract][Full Text] [Related]
26. Cancer vaccine development: on the way to break immune tolerance to malignant cells.
Mocellin S; Rossi CR; Nitti D
Exp Cell Res; 2004 Oct; 299(2):267-78. PubMed ID: 15350526
[TBL] [Abstract][Full Text] [Related]
27. Immunization delivered by lentiviral vectors for cancer and infectious diseases.
Hu B; Tai A; Wang P
Immunol Rev; 2011 Jan; 239(1):45-61. PubMed ID: 21198664
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
29. Cancer vaccines: on the threshold of success.
Emens LA
Expert Opin Emerg Drugs; 2008 Jun; 13(2):295-308. PubMed ID: 18537522
[TBL] [Abstract][Full Text] [Related]
30. Cancer vaccines: what do we need to measure in clinical trials?
Kudrin A
Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
[TBL] [Abstract][Full Text] [Related]
31. Whole cell vaccines--past progress and future strategies.
Keenan BP; Jaffee EM
Semin Oncol; 2012 Jun; 39(3):276-86. PubMed ID: 22595050
[TBL] [Abstract][Full Text] [Related]
32. Towards a therapeutic breast cancer vaccine: the next steps.
Emens LA
Expert Rev Vaccines; 2005 Dec; 4(6):831-41. PubMed ID: 16372879
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic cancer vaccines.
Morris LF; Ribas A
Surg Oncol Clin N Am; 2007 Oct; 16(4):819-31, ix. PubMed ID: 18022546
[TBL] [Abstract][Full Text] [Related]
34. Use of tumour-responsive T cells as cancer treatment.
Disis ML; Bernhard H; Jaffee EM
Lancet; 2009 Feb; 373(9664):673-83. PubMed ID: 19231634
[TBL] [Abstract][Full Text] [Related]
35. Update on vaccines for solid tumors.
Gajewski TF
Clin Adv Hematol Oncol; 2004 Mar; 2(3):158-9. PubMed ID: 16166944
[No Abstract] [Full Text] [Related]
36. Immunization in tumor prevention.
Forni G; Curcio C; Spadaro M; Iliffe J; Quaglino E; Di Carlo E; Musiani P; Lollini PL
Int Immunopharmacol; 2003 Aug; 3(8):1151-8. PubMed ID: 12860170
[TBL] [Abstract][Full Text] [Related]
37. Immunologic approaches to antigen discovery for cancer vaccines.
Jones LA; Salgaller ML
Expert Opin Investig Drugs; 2000 Mar; 9(3):481-90. PubMed ID: 11060689
[TBL] [Abstract][Full Text] [Related]
38. Cancer vaccines: between the idea and the reality.
Finn OJ
Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
[TBL] [Abstract][Full Text] [Related]
39. Cancer vaccination.
Del Vecchio M; Parmiani G
Forum (Genova); 1999; 9(3):239-56. PubMed ID: 10504171
[TBL] [Abstract][Full Text] [Related]
40. Vaccines and other immunological approaches for cancer immunoprevention.
Lollini PL; Nicoletti G; Landuzzi L; Cavallo F; Forni G; De Giovanni C; Nanni P
Curr Drug Targets; 2011 Dec; 12(13):1957-73. PubMed ID: 21158706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
